---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-011876"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2026-08-04T20:05:36+00:00"
generated_at: "2026-08-04T20:07:58.610948+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precigen reports Q2 2026 net income of $20.1M; PAPZIMEOS revenue $53.1M, more than double prior quarter

## Summary
- PAPZIMEOS net revenue $53.1M in Q2 2026, more than double prior quarter; total revenues $55.0M.
- Net income $20.1M ($0.06 basic EPS) vs net loss $26.6M ($0.09 loss) in Q2 2025.
- Cash, equivalents, and investments $38.7M as of June 30, 2026; expects cash flow break-even by end of 2026.
- FDA granted PAPZIMEOS seven-year market exclusivity; patient hub enrollment over 500 patients.
- MAA for PAPZIMEOS under review by EMA; PRGN-2009 pipeline update expected by year-end.

## SEC filing metadata
- accession: 0000950103-26-011876
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2026-08-04T20:05:36+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/0000950103-26-011876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010326011876/dp251262_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-011876
- JSON: https://secwatch.observer/filing/0000950103-26-011876.json
- Plain text: https://secwatch.observer/filing/0000950103-26-011876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.